Jeffrey Allan Zonder | oneAMYLOIDOSISvoice

Jeffrey Allan Zonder, MD

Department of Oncology
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan, United States
Jeffrey Allan Zonder, MD, is Professor in the Department of Oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine. He received his medical degree from Wayne State University School of Medicine. He completed his medical residency at the University of Rochester in Rochester, New York, before returning to Wayne State University for Hematology-Oncology fellowship training. Dr. Zonder is the leader of the KCI Myeloma and Amyloidosis Multidisciplinary sub-team, a medical advisor for the Amyloidosis Support Group Networks, and a member of the International Myeloma Working Group, the International Myeloma Society and the International Society of Amyloidosis.
He is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Medical Association and the SWOG Barlogie-Salmon Myeloma Committee. He was the national principal investigator of the SWOG study S0232, a randomized trial that helped establish the efficacy of lenalidomide and dexamethasone as initial treatment for myeloma. Dr. Zonder has authored or co-authored numerous original research papers, review articles, book chapters, and research abstracts on myeloma and amyloidosis. Dr. Zonder chaired two Untangling Amyloidosis Friday Satellite Symposia at ASH in 2015 and 2018, founded the online amyloidosis journal club #AmyloidosisJC, and regularly participates as a speaker at amyloidosis patient support groups.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.